NASDAQ:TIL
Instil Bio, Inc.
Instil Bio, Inc. reported net income of −$71.4M in fiscal 2025. The diluted share count rose 2.4%.Summary generated from Instil Bio, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−50.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+2.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | n/a | n/a | n/a | n/a |
| Operating income | −156 | −226 | −159 | −74 | −79 |
| Net income | −157 | −223 | −156 | −74 | −71 |
| Free cash flow | −180 | −265 | −103 | −56 | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 4Insider transaction report
Jun 12, 2026 - 4Insider transaction report
Jun 12, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 8-KResults of operations and financial condition
May 15, 2026 - DEF 14AProxy statement
Apr 24, 2026